PHARMANDERLECHT
ActivePHARMANDERLECHT has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €131k and a net result of €-16k. Equity is growing by ~44.9% per year across the filed fiscal years. Its solvency ranks better than 58% of 4157 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).
Checked score
Score 2025
51
/ 100
Fair
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability12▼-78
Solvency68▼-7
Growth78=
Track record100
Bankruptcy probability, 12 months
1.3%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €6k at 30 days acceptable
Liquidity ample (current ratio 1.69 against 1.86 in 2024; short-term debt: 57% and cash: 24.2% of total assets), but 57% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 12-03-2026, 49 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
49 d early
2024
47 d early
2023
61 d early
2022
31 d early
2021
37 d early
2020
52 d early
2019
58 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-09-2026 and is due by 30-04-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
23-09-2026 today30-09-2026 close30-04-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€-16k
2024 · €51k
2018: €-33k
2019: €-47k
2020: €19k
2021: €64k
2022: €65k
2023: €65k
2024: €51k
2018 → 2025
Working capital
€119k▲ 9.7%
2024 · €109k
2018: €116k
2019: €74k
2020: €44k
2021: €46k
2022: €64k
2023: €72k
2024: €109k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-33k-€31k€96k▲ 206%€147k▲ 52.8%€131k▼ 10.9%
Operating result€73k-€86k▲ 17.8%€91k▲ 6.1%€70k▼ 23.1%€-14k
Net result€64k-€65k▲ 1.4%€65k▼ 0.1%€51k▼ 21.6%€-16k
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2025: a loss of €14k after €70k in 2024, the lowest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €304k
Fixed assets
€12k▼ 80.3%
Current assets
€293k▲ 24.6%
Equity and liabilities €304k
Equity
€131k▼ 10.9%
Debt
€174k▲ 17.7%
The debt ratio rises from 50.1% to 57.0%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€-8k▼
2024 · €86k
Cash flow
€-10k▼
2024 · €67k
Solvency
43.0%▼
2024 · 49.9%
Current ratio
1.69▼
2024 · 1.86
Quick ratio
0.98▲
2024 · 0.82
Debt / equity
1.33▲
2024 · 1.00
ROE
-12.2%▼
2024 · 34.6%
ROA
-5.2%▼
2024 · 17.2%
Interest coverage
-3.40▼
2024 · 20.06
Debt
€174k▲
2024 · €147k
Debt ≤ 1 year
€174k▲
2024 · €126k
Staff costs
€228k▲
2024 · €222k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€294k€304k▲
Fixed assets21/28€59k€12k▼
Tangible fixed assets22/27€59k€12k▼
Plant, machinery and equipment23€17k€12k▼
Furniture and vehicles24€43k€25▼
Current assets29/58€235k€293k▲
Stocks and contracts in progress3€131k€123k▼
Stocks30/36€131k€123k▼
Amounts receivable within one year40/41€58k€95k▲
Trade receivables40€50k€87k▲
Other amounts receivable41€8k€8k▲
Current investments50/53€500€500=
Cash at bank and in hand54/58€40k€74k▲
Deferred charges and accrued income490/1€5k€342▼
Equity and liabilities
Total equity and liabilities10/49€294k€304k▲
Equity10/15€147k€131k▼
Contributions10/11€12k€12k=
Reserves13€2k€2k=
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Profit (loss) carried forward14€133k€117k▼
Amounts payable17/49€147k€174k▲
Amounts payable after more than one year17€21k-
Financial debts170/4€21k-
Amounts payable within one year42/48€126k€174k▲
Current portion of amounts payable after more than one year42€10k-
Financial debts43€4k-
Credit institutions430/8€4k-
Trade debts44€86k€97k▲
Suppliers440/4€86k€97k▲
Taxes, remuneration and social security45€27k€38k▲
Taxes450/3€467-
Remuneration and social security454/9€27k€38k▲
Other amounts payable47/48-€39k
Income statement
Code20242025
Remuneration, social security and pensions62€222k€228k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€16k€6k▼
Other operating charges640/8€10€12k▲
Gross operating margin9900€308k€232k▼
Operating profit (loss)9901€70k€-14k▼
Financial charges65/66B€4k€2k▼
Recurring financial charges65€4k€2k▼
Profit (loss) for the period before taxes9903€66k€-16k▼
Income taxes67/77€15k-
Profit (loss) for the period9904€51k€-16k▼
Profit (loss) for the period to be appropriated9905€51k€-16k▼
Appropriation of the result
Profit (loss) to be appropriated9906€133k€117k▼
Profit (loss) brought forward from the previous period14P€82k€133k▲
Social balance
Average headcount (FTE)90873.23.2=
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
12-03
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
14-03
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
30-09
Financial
Equity above €100kEq €147k ▲52.8%
5 profitable years in a row build equity to €147k.
29-02
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
30-03
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
30-09
Financial
Highest result since 2018net €65k ▲1.4%
Net result €65k, the highest in the series.
24-03
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
09-03
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
30-09
Financial
Back to profitnet €19k
Net result €19k after 2 loss-making years.
03-03
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
30-09
Financial
Weakest financial yearnet €-47k
Net result drops to €-47k, the lowest in the series; recovery starts the following year.
18-03
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
15-03
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
14-03
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Anderlecht · 1 establishment unit since 2009
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Henri Reysquare 31070 AnderlechtGround area
119 m²
Building footprint
92 m²
Volume, LiDAR
1,099 m³
Parcel 21302A0056/00D008, Brussels · tallest building 16.7 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
Pharmanderlecht
since 20092.181.325.112
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21302A0056/00D008 | Brussels | 119 m² | 1 · 92 m² | 16.7 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteAnderlecht2.181.325.112
Similar companies · same sector, comparable size
APOTHEEK HENDRICKX
BE 0436.699.344
Hasselt · Eq €131k
Pharmacie de Lincent
BE 0672.748.745
Lincent · Eq €131k
PHARMACIE BOULANGER
BE 0830.717.106
Jette · Eq €131k
CHARLOTTE DE CHAFFOY
BE 0808.914.474
Brussel · Eq €131k
GREMASTER
BE 0887.786.065
Ronse · Eq €131k
Of 5,222 companies in sector 47730 we hold annual accounts for 3,861. 3,535 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded15-09-2009
Fiscal year end30-09
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 16 filingsAddress and cadastre registers
Data from official sources, last processed on 21-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryPhone:0494/153155